MedTrace Logo

Efficacy and Safety Assessment of T4030 Eye Drops Versus Ganfort® UD in Ocular Hypertensive or Glaucomatous Patients.

NCT04898387 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 554

Last updated 2023-07-21

No results posted yet for this study

Summary

To demonstrate the non-inferiority of T4030 unpreserved eye drops compared to Ganfort® UD in terms of efficacy.

Conditions

  • Ocular Hypertension Glaucoma

Interventions

COMBINATION_PRODUCT

Bimatoprost Timolol (T4030)

Eye drop

COMBINATION_PRODUCT

Bimatoprost Timolol (Ganfort)

Eye drop

Sponsors & Collaborators

  • Laboratoires Thea

    lead INDUSTRY

Principal Investigators

  • CORENTIN LECAMUS · Laboratoires Thea

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-03-26
Primary Completion
2023-04-13
Completion
2023-05-30

Countries

  • Bulgaria

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04898387 on ClinicalTrials.gov